Filing Details
- Accession Number:
- 0000937556-20-000021
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-06 17:16:12
- Reporting Period:
- 2020-02-04
- Accepted Time:
- 2020-02-06 17:16:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
937556 | Masimo Corp | MASI | Electromedical & Electrotherapeutic Apparatus (3845) | 330368882 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1575205 | Samuel Thomas Mcclenahan | C/O Masimo Corporation 52 Discovery Irvine CA 92618 | Evp & General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-02-04 | 1,200 | $19.72 | 7,464 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-04 | 1,200 | $176.01 | 6,264 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-02-05 | 7,477 | $19.72 | 13,741 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-05 | 7,477 | $176.50 | 6,264 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-02-06 | 1,323 | $19.72 | 7,587 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-06 | 1,323 | $176.04 | 6,264 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (Right to Buy) | Disposition | 2020-02-04 | 1,200 | $19.72 | 1,200 | $19.72 |
Common Stock | Non-Qualified Stock Option (Right to Buy) | Disposition | 2020-02-05 | 7,477 | $19.72 | 7,477 | $19.72 |
Common Stock | Non-Qualified Stock Option (Right to Buy) | Disposition | 2020-02-06 | 1,323 | $19.72 | 1,323 | $19.72 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
11,800 | 2014-04-25 | 2023-04-25 | No | 4 | M | Direct |
4,323 | 2014-04-25 | 2023-04-25 | No | 4 | M | Direct |
3,000 | 2014-04-25 | 2023-04-25 | No | 4 | M | Direct |
Footnotes
- The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of August 7, 2019, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 represents the weighted average sale price per share. The actual sale prices ranged from a low of $176.0000 per share to a high of $176.0250 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The price reported in Column 4 represents the weighted average sale price per share. The actual sale prices ranged from a low of $176.0150 per share to a high of $177.5100 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The price reported in Column 4 represents the weighted average sale price per share. The actual sale prices ranged from a low of $176.0000 per share to a high of $176.0900 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This option was granted on April 25, 2013 and was exercisable as the option vested. This option vested over a five-year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.